Our results indicate that EGFR-TKI increases surface expression of EGFR and/or HER2 only in erlotinib sensitive NSCLC cell lines and, in turns, leads to increased susceptibility to ADCC both in vitro and in xenograft models. Here, ERBB2 is linked to non-small cell lung carcinoma.